{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T11:35:15Z","timestamp":1775129715646,"version":"3.50.1"},"reference-count":0,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["ACAMC"],"published-print":{"date-parts":[[2021,7,9]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Tenosynovial giant cell tumor refers to a group of rarely occurring tumors that are\nformed in the joints, which are characterized by pain, swelling, and limitation of movement of the joint. Surgery\nis the main treatment strategy, but the tumor is likely to recur, especially in pigmented villonodular synovitis,\nwhich is the diffuse-type giant cell tumor. Pexidartinib was approved in August 2019 by the Food and Drug\nAdministration (FDA) with a brand name TURALIO as the first systemic approved therapy for patients having\nTenosynovial Giant Cell Tumors (TGCT).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>In this review, different aspects pertaining to pexidartinib have been summarized, including the\npathophysiology of TGCT, chemistry, pharmacokinetics and pharmacodynamics of pexidartinib. Special\nattention is given to various reported clinical trials of pexidartinib.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>A comprehensive literature search was conducted in the relevant databases to identify studies\npublished in this field during recent years.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Pexidartinib acts by inhibiting the Colony-Stimulating Factor (CSF1)\/CSF1 receptor pathway,\nwhich leads to the inhibition of the cell lines proliferation and promotes the autophosphorylation process of the\nligand-induced CSF1 receptor. Pexidartinib emerged as a potential drug candidate for the treatment of TGCT.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871520620999201102123555","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T07:54:51Z","timestamp":1604476491000},"page":"1510-1519","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review"],"prefix":"10.2174","volume":"21","author":[{"given":"Yunes M.M.A.","family":"Alsayadi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, ISF College of Pharmacy, G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7844-9172","authenticated-orcid":true,"given":"Pooja A.","family":"Chawla","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry & Analysis, ISF College of Pharmacy, G.T. Road, Moga-142 001, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","container-title":["Anti-Cancer Agents in Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/187446","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187446\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/187446","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T14:10:36Z","timestamp":1626271836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187446\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,7,9]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871520620999201102123555","relation":{},"ISSN":["1871-5206"],"issn-type":[{"value":"1871-5206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7,9]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-07-06","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}